Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split CHATHAM, N.J.

Tonix Pharmaceuticals Form 8-K

Tonix Pharmaceuticals Announces 1-for-100 Reverse

CHATHAM, N.J., February 3, 2025 (GLOBE NEWSWIRE) --

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed

products and a pipeline of development candidates, today announced that it will effect a 1-for-100 reverse stock split of its outstanding

common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on February 5, 2025.

The reverse stock split is intended to increase the

per share trading price of Tonix's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The

NASDAQ Capital Market (Rule 5550(a)(1)). Tonix's common stock will continue to trade on the NASDAQ Capital Market under the symbol

"TNXP" and under a new CUSIP number, 890260839. As a result of the reverse stock split, every one hundred pre-split shares

of common stock outstanding will become one share of common stock. The reverse split will also apply to common stock issuable upon the

exercise of Tonix's outstanding warrants and stock options. The reverse stock split will not proportionately reduce the number of

shares of authorized common stock, as permitted under Nevada law, as shareholder approval for the reverse stock split was obtained on

Tonix's transfer agent, VStock Transfer LLC,

which is also acting as the exchange agent for the reverse split, will provide instructions to shareholders regarding the process for

exchanging share certificates. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the

nearest whole post-split share and no shareholders will receive cash in lieu of fractional shares.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company

focused on transforming therapies for pain management and vaccines for public health challenges. Tonix's development portfolio is

focused on central nervous system (CNS) disorders. Tonix's priority is to advance TNX-102 SL, a product candidate for the management

of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia

and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization.

The FDA has previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed

to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS

study funded by the U.S. Department of Defense (DoD). Tonix's CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in

Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported

by a grant from the National Institute on Drug Abuse. Tonix's immunology development portfolio consists of biologics

to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody

targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.

Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. In July 2024, Tonix announced

a contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200,

small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness

of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility

in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra

(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

Zembrace SymTouch and Tosymra are registered trademarks

of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix

can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking

within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking

words such as "anticipate," "believe," "forecast," "estimate," "expect," and

"intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could

differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking

statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance

with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress

of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation;

uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties;

and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory

approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement.

Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with

the Securities and Exchange Commission (the "SEC") on April 1, 2024, and periodic reports filed with the SEC on or after the

date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The information set forth herein speaks only as of the date thereof.

Tonix Pharmaceuticals

Indication and Usage

Zembrace SymTouch (sumatriptan succinate)

injection (Zembrace) and Tosymra (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches

with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known

if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart

attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

Zembrace and Tosymra are not for people with risk factors for heart disease

(high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

Tell your provider about all of your medical conditions and medicines you

take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so,

do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

The most common side effects of Zembrace and Tosymra include: pain and

redness at injection site (Zembrance only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your

face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only)

and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does

not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra

but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can

also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to

the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.